EHS
EHS

FDA accepts new drug application for liver cancer T-cell therapy



Eureka Therapeutics announced that the FDA has cleared its investigational new drug application for ET140202 ARTEMIS T-cell therapy for patients with hepatocellular carcinoma who are positive for alpha-fetoprotein, according to a press release.
“This is an exciting time for Eureka as we prepare to initiate our U.S. clinical trial in patients with hepatocellular carcinoma,” Cheng Liu, PhD, president and CEO of Eureka Therapeutics, said in the release. “HCC is an area of significant unmet medical need and patient options are currently limited. We intend to advance ET140202 as

Source link

EHS
Back to top button